uniQure N.V. (NASDAQ:QURE – Get Free Report) traded up 7.2% during mid-day trading on Wednesday . The company traded as high as $28.72 and last traded at $28.69. 716,792 shares were traded during mid-day trading, a decline of 73% from the average session volume of 2,658,588 shares. The stock had previously closed at $26.76.
Analysts Set New Price Targets
A number of analysts have issued reports on the stock. The Goldman Sachs Group boosted their price objective on shares of uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Monday, April 20th. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $15.00 to $60.00 in a report on Monday, March 9th. Chardan Capital boosted their price objective on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Barclays cut their price objective on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a report on Monday, March 23rd. Finally, TD Cowen reissued a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.83.
Check Out Our Latest Research Report on QURE
uniQure Stock Down 6.3%
uniQure (NASDAQ:QURE – Get Free Report) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, sell-side analysts forecast that uniQure N.V. will post -3.68 EPS for the current fiscal year.
Insider Activity at uniQure
In other news, insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00. Following the completion of the transaction, the insider directly owned 169,669 shares in the company, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 4.65% of the company’s stock.
Hedge Funds Weigh In On uniQure
Several hedge funds and other institutional investors have recently made changes to their positions in QURE. Torren Management LLC acquired a new position in shares of uniQure in the 4th quarter valued at approximately $28,000. Jones Financial Companies Lllp raised its position in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 509 shares in the last quarter. IFP Advisors Inc acquired a new position in shares of uniQure in the 4th quarter valued at approximately $48,000. Smartleaf Asset Management LLC acquired a new position in uniQure during the 4th quarter worth approximately $48,000. Finally, CIBC Private Wealth Group LLC acquired a new position in uniQure during the 3rd quarter worth approximately $50,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.
About uniQure
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
Read More
- Five stocks we like better than uniQure
- NVIDIA Sends a Message With RTX Spark—This Is What It Says
- Buy the Dip? Broadcom’s AI Moat Is Wider Than Ever
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
-PUNDIX.png){kind=small}
